Q4 2024 Moleculin Biotech Inc Earnings Call Transcript
Key Points
- Moleculin Biotech Inc (MBRX) has initiated the MIRACLE Phase 3 pivotal trial for Annamycin, targeting relapsed and refractory AML patients, with 25 sites selected globally.
- The company has regulatory and ethics approval in its first European country and expects more approvals in the second quarter.
- Annamycin has shown promising Phase 2 data with a 50% complete remission rate in second-line AML patients, outperforming existing therapies.
- The MIRACLE trial includes multiple unblindings of data, providing stakeholders with visibility into the trial's progress.
- Moleculin Biotech Inc (MBRX) has reduced operating expenses by $3 million in 2024 compared to 2023, demonstrating financial discipline.
- The US is expected to be one of the last countries to begin enrolling in the MIRACLE trial due to longer approval processes.
- The company faces a significant financial challenge, with the Phase 3 trial potentially costing upwards of $60 million to $70 million.
- Moleculin Biotech Inc (MBRX) has a limited cash runway, with funds expected to last only until the third quarter of 2025.
- There is uncertainty regarding which Annamycin dosing regimen will be most effective, requiring further data analysis.
- The company acknowledges the complexity of achieving early approval, as it requires a very statistically significant result in Part A of the trial.
Hello, and welcome to the Moleculin Biotech fourth quarter and full year 2024 update conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded.
At this time, I'd like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations, or future projections. These are forward-looking statements that involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the Federal Securities Laws and are based on Moleculinâs current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results different materially from these contemplated by such forward-looking statements are discussed in the periodic reports Moleculin files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
